Last reviewed · How we verify
D-0316 Capsule
D-0316 Capsule is a small molecule that targets the molecular target.
D-0316 Capsule is a small molecule that targets the molecular target. Used for Phase 2 clinical trial for treatment of unspecified condition.
At a glance
| Generic name | D-0316 Capsule |
|---|---|
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of D-0316 Capsule is not well understood, but it is believed to work by interacting with the molecular target, leading to a therapeutic effect.
Approved indications
- Phase 2 clinical trial for treatment of unspecified condition
Common side effects
- Unknown
Key clinical trials
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |